Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 10/20 | 0.38 |
| ▸ | ARG2 | P78540 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148366 | 0.85 | ODC1 (0.54) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL31588249 | 0.82 | — | — | |
| SCHEMBL691126 | 0.80 | — | — | |
| SCHEMBL16222762 | 0.79 | MEN1 (0.47) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL5321451 | 0.79 | MEN1 (0.47) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL18084239 | 0.79 | PAOX (0.34) | ODC1THRBKDM4EMAPTBLM | |
| Hydrochloric Acid SCHEMBL2748363 | 0.78 | ARG2 (0.44) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL5324175 | 0.76 | MEN1 (0.65) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL16222760 | 0.76 | ARG2 (0.46) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL4318239 | 0.76 | GGT1 (0.53) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221736-A1 | METHOD FOR PREDICTING SUSCEPTIBILITY TO A MENTAL DISORDER | FONDATION ALAMAYA (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20090297494-A1 | Diagnostic and treatment of a mental disorder | CUENOD MICHEL | 2009-12-03 | — | — | US | disclosed |
| US-20060275536-A1 | GRAIN PRODUCT WITH INCREASED SOLUBLE FIBER CONTENT AND ASSOCIATED METHODS | GENERAL MILLS IP HOLDINGS II, LLC | 2006-12-07 | — | — | US | disclosed |
| US-20060216394-A1 | Method and compositions to decrease serum cholesterol levels | GENERAL MILLS IP HOLDINGS II, LLC | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297494-A1 | Diagnostic and treatment of a mental disorder | GSTA1, GSR, GSTM1 | ODC1 2789/4885MEN1 4806/4885ALDH1A1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.